UNSPSC 51384609: Oxyphenbutazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H806S4B3NS, chemically known as 3,5-pyrazolidinedione, 4-butyl-1-(p-hydroxyphenyl)-2-phenyl- (van) (8ci) but generally known as oxyphenbutazone, which bears US NIH Compound Identifier 4641. European Medicines Agency schedules Oxyphenbutazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09572MIG.

UNSPSC 51384609 Oxyphenbutazone, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The single recent opportunity posted under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and safe drug deactivation systems, not oxyphenbutazone (a nonsteroidal anti-inflammatory drug). The mismatch between the code designation and the actual procurement suggests either a tagging error in the county's e-procurement system or a broader use of the oxyphenbutazone code that does not reflect pharmaceutical procurement in the traditional sense.

Seminole County's IFB, posted June 30, 2026, with a response deadline of July 26, 2023 (dates that conflict in the source record), requires annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract runs two years with a one-year renewal option, includes a three-month probationary termination clause, and carries potential FEMA funding with accompanying federal compliance requirements. Vendors must submit electronic bids through the county's e-procurement portal, include shipping and delivery costs in pricing, maintain workers' compensation and commercial general liability insurance, and satisfy E-Verify employment eligibility verification. The procurement does not specify set-aside designations. Given the single and misaligned opportunity in the recent posting block, this code presents no clear procurement signal for business development targeting oxyphenbutazone or related pharmaceutical commodities at the state and local level.